Drug Type CAR-T |
Synonyms- |
Target |
Action antagonists |
Mechanism TWEAKR antagonists(TNF receptor superfamily member 12A antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glioblastoma | Preclinical | United States | 21 Apr 2026 | |
| Metastatic castration-resistant prostate cancer | Preclinical | United States | 21 Apr 2026 | |
| Renal Cell Carcinoma | Preclinical | United States | 21 Apr 2026 |





